Vaccinex Current Ratio 2017-2021 | VCNX

Vaccinex current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Vaccinex Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.02B $0.01B 4.10
2021-03-31 $0.03B $0.01B 4.48
2020-12-31 $0.01B $0.01B 0.86
2020-09-30 $0.02B $0.01B 1.32
2020-06-30 $0.00B $0.01B 0.34
2020-03-31 $0.00B $0.01B 0.65
2019-12-31 $0.00B $0.01B 0.58
2019-09-30 $0.01B $0.01B 1.50
2019-06-30 $0.01B $0.01B 0.69
2019-03-31 $0.01B $0.01B 1.83
2018-12-31 $0.02B $0.01B 3.20
2018-09-30 $0.03B $0.01B 4.78
2018-06-30 $0.00B $0.01B 0.28
2018-03-31 $0.00B $0.01B 0.71
2017-12-31 $0.01B $0.00B 1.19
2017-09-30 $0.00B 0.00
2017-06-30 $0.00B 0.00
2017-03-31 $0.00B 0.00
2016-12-31 $0.00B $0.00B 0.48
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.056B $0.001B
Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company's product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76